[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematologic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematologic-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,77,101,138,165,187,209,245,272,297,319,345,369,397],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100464108","improving-comprehensive-care-of-cancer-patients-100464108",false,"NCT05323409","Improving Comprehensive Care of Cancer Patients","Optimise: Improving Comprehensive Care of Cancer Patients With Comorbidities","Inclusion Criteria:\n\n* For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2) treatment with standard, definitive therapies (may include one or more modalities) 3) presence of one or more chronic comorbidities (e.g., diabetes, hypertension) and\u002For unhealthy lifestyle behaviors (e.g., overweight\u002Fobesity, current smoker, alcohol use) that require ongoing management during cancer treatment 4) age \\>18 years 5) fluency in English or Spanish 6) ability to provide informed consent 7) assignment to a Harris Health oncologist and PCP who are willing to participate and will provide informed consent.\n\nFor healthcare providers: 1) Person is an oncologist or PCP who treats patients with breast, GI, or hematologic malignancies at Harris Health BT\u002FSmith Clinic\n\nExclusion Criteria:\n\n* For Patients: Significant cognitive impairment or Lack of capacity to consent For Providers: None",true,"ALL","18 Years",{"count":20,"type":21},340,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Medically underserved patients, who bear the highest burden of multiple chronic conditions, are at increased risk for poor outcomes during and after cancer treatment. Enhancing communication and collaboration between oncologists and primary care providers (PCPs) could improve health outcomes and care transitions for these patients, who often lack healthcare knowledge and access to supportive care.\n\nThis study evaluates a novel shared care model for cancer survivors with chronic comorbidities, called OPTIMISE (Oncology-Primary Care Partnership to Improve Comprehensive Survivorship Care), in the largest safety-net healthcare system in Houston, Texas. Three hundred newly diagnosed breast, gastrointestinal, and hematological cancer patients being treated with curative intent and having comorbidities requiring ongoing management will be randomized to either OPTIMISE or Usual Medical Care (UMC). UMC patients will receive cancer treatment directed by their oncologist, a survivorship care plan (SCP) at the end of active treatment, and surveillance visits based on national guidelines.\n\nOPTIMISE patients will: 1) have an oncology nurse navigator assigned to their care team at diagnosis to facilitate oncologist-PCP communication; 2) receive coordinated care between their oncologist and PCP throughout cancer treatment and surveillance, facilitated by structured communication and referral processes; 3) receive an SCP that incorporates comorbidity management; and 4) follow a risk-stratified shared care model where some routine oncologist follow-up visits are replaced by PCP visits. Aim 1a evaluates OPTIMISE's impact on patient chronic disease self-management (primary outcome) and quality of life (secondary outcome). Aim 1b explores OPTIMISE's effects on healthcare use and patient unmet needs during and after treatment. Aim 2 examines OPTIMISE's impact on oncologist and PCP attitudes and care coordination. Aim 3 elucidates patient- and system-level factors influencing implementation outcomes. If effective, OPTIMISE could expand to other cancers and enhance care transitions in various medical settings.",[27,28,29],"Breast Cancer","Gastrointestinal Cancer","Hematologic Cancer","RECRUITING","2026-06-26",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":34},"2022-04-01",{"date":38,"type":21},"2027-06",{"name":40,"class":41},"Baylor College of Medicine","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100640447","digitalized-exercise-fit-tool-intervention-for-adolescents-with-blood-cancer-100640447","NCT07621887","Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer","Digitalised Exercise Fit Tool Intervention for Adolescents With Hematologic Cancer","Inclusion Criteria:\n\n* (1) they are 12-18 years old;\n* (2) they had been diagnosed with hematologic cancer such as leukaemia and lymphoma;\n* (3) they are regarded by the responsible physicians as stable, able to conduct PA, and without any PA restrictions,\n* (4) they completed all cancer treatment;\n* (5) they speak Cantonese and read Chinese.\n\nExclusion Criteria:\n\n* (1) Receiving palliative care\n* (2) Have physical or cognitive impairment and learning problems as identified from medical records\n* (3) Identified by physicians that no physical activity should be conducted at the time of recruitment","12 Years",{"count":52,"type":21},30,[24],"The goal of this clinical trial is to learn if a digitalised Exercise Fit Tool (EFT) mobile application can promote physical activity in adolescents aged 12-18 years who have completed treatment for hematologic cancer (e.g., leukaemia and lymphoma). The main questions it aims to answer are:\n\n1. Is it feasible to conduct a larger randomised controlled trial of the digitalised EFT intervention?\n2. Does the digitalised EFT intervention improve physical activity levels, physical activity self-efficacy, and quality of life at 6 months?\n\nResearchers will compare the digitalised EFT intervention group to a usual care group to see if the mobile application can promote physical activity levels, physical activity self-efficacy, and quality of life in adolescents with hematologic cancer.Participants will:\n\n1. Receive a 20-minute educational session on how to use the mobile application\n2. Use the mobile application to self-assess their appropriate physical activity level and exercise with a virtual coach\n3. Complete questionnaires and wear an accelerometer at 1, 3, and 6 months after enrollment\n4. Attend a 20-30-minute individual interview at 6 months (intervention group only, 10 participants)",[29,56,57,58],"Leukaemia","Lymphoma","Physical Activity",[60,61,62,63,64,65,66,67],"Adolescents","Cancer","Physical activity","Mobile application","Feasibility randomised controlled trial","Exercise Fit Tool","Quality of life","Digital intervention","NOT_YET_RECRUITING","2026-06-01",{"date":71,"type":34},"2026-06-02",{"date":69,"type":21},{"date":74,"type":21},"2027-12-31",{"name":76,"class":41},"The Hong Kong Polytechnic University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":42},"100545066","early-detection-of-complications-during-immunotherapy-for-haematological-malignancy-100545066","NCT06377059","Early Detection of Complications During Immunotherapy for Haematological Malignancy","Early Detection of Complications During Immunotherapy for Haematological Malignancy - Description of Associated Vital Signs and Immune Responses","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients diagnosed with haematologic malignant disease (e.g. malignant lymphoma)\n* Patients scheduled for treatment with CART or BsAbs\n\nExclusion Criteria:\n\n* Patient is pregnant\n* Patient has a pacemaker\n* Patient is allergic to one or more of the materials that the equipment consists of\n* Investigator deems patient not able to comply with participation in the study",{"count":85,"type":21},100,[24],"Aims\n\n* To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications\n* Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.",[29,89],"CRS - Cytokine Release Syndrome",[91],"wireless monitoring","2026-05-12",{"date":94,"type":34},"2026-05-15",{"date":96,"type":34},"2024-12-02",{"date":98,"type":21},"2027-07-01",{"name":100,"class":41},"Rigshospitalet, Denmark",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":123,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100450172","avera-cancer-sequencing-and-analytics-protocol-asap-100450172","NCT05142033","Avera Cancer Sequencing and Analytics Protocol (ASAP)","Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)","ASAP","Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer\n* Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation\n\nExclusion Criteria:\n\n* Participants incapable of understanding the items listed in the consent form and process\n* Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements",{"count":110,"type":21},25000,"OBSERVATIONAL","The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types.\n\nComprehensive molecular profiling will include somatic tumor testing (tissue and\u002For blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and\u002For whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples.\n\nTo maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research.\n\nData collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.",[61,114,115,27,116,117,118,119,120,121,122,29],"Cancer Diagnosis","Early Detection of Cancer","Lung Cancer","Colon Cancer","GI Cancer","Gynecologic Cancer","Ovarian Cancer","Endometrial Cancer","CNS Cancer",[61,124,125,126,127],"Genomics","Genetics","Microbiome","Pharmacogenomics","2026-03-23",{"date":130,"type":34},"2026-03-27",{"date":132,"type":34},"2021-11-01",{"date":134,"type":21},"2026-12-31",{"name":136,"class":41},"Avera McKennan Hospital & University Health Center",6,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100606254","non-pharmacological-interventions-for-neurotoxicity-in-hematologic-patients-receiving-car-t-therapy-100606254","NCT07173166","Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy","Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy of Non-Pharmacological Interventions on Neurotoxicity Associated With CAR-T Therapy in Hematologic Patients","CARE-T","Inclusion Criteria:\n\n* Male and female patients, aged 18 to 80 years.\n* Diagnosed with a hematological condition.\n* Initiating antineoplastic treatment with CAR-T cell therapy.\n\nExclusion Criteria:\n\n* Presence of language barriers or physical and\u002For cognitive impairments that hinder the understanding of the interventions or prevent proper completion of the assessment tools used in the study.\n* Pre-existing neurological or psychiatric comorbidities that may interfere with the evaluation of neurotoxic effects of the hematologic treatment.\n* Concomitant treatment with additional neurotoxic drugs not related to the study protocol.\n* History of abusive consumption of neurotoxic substances.","80 Years",{"count":85,"type":21},[24],"The goal of this clinical trial is to learn if two non-pharmacological strategies can help reduce neurotoxicity caused by CAR-T cell therapy in adult patients with hematologic cancer, both sexes, aged 18 to 80 years. The strategies are:\n\n* A structured physical activity program.\n* A combination of physical activity and nutritional recommendations.\n\nThe main questions it aims to answer are:\n\n* Does physical activity help lower the risk or severity of neurotoxicity after CAR-T therapy?\n* Does combining physical activity with nutritional recommendations provide greater protection against neurotoxicity than physical activity alone?\n\nResearchers will compare two intervention groups with a control group (no intervention) to see which approach is most effective in reducing neurotoxicity and improving recovery.\n\nParticipants will be randomly assigned to one of three groups using stratified randomization to ensure balanced clinical and demographic characteristics:\n\n* Group A: Structured physical activity program.\n* Group B: Structured physical activity program combined wuth nutritional recommendations.\n* Group C: No intervention; used to establish baseline patterns.\n\nParticipants will be evaluated periodically by study professionals. Comprehensive records of symptoms, health measurements, and relevant lifestyle data will be maintained throughout the study.",[29],[152,153,154,62],"CAR-T therapy","Neurotoxicity","Nutrition","2026-03-07",{"date":157,"type":34},"2026-03-10",{"date":159,"type":34},"2025-09-30",{"date":161,"type":21},"2028-09",{"name":163,"class":41},"Instituto de Investigacion Sanitaria INCLIVA",2,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100628019","the-efficacy-and-safety-of-stereotactic-radiotherapy-bridging-allogeneic-hematopoietic-stem-cell-transplantation-for-the-treatment-of-hematological-malignance-patients-with-extramedullary-infiltrating-100628019","NCT07456189","The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating","Inclusion Criteria:\n\nSubjects who meet all of the following criteria are eligible for enrollment in this study:\n\n* Age between 18 and 60 years.\n* A confirmed diagnosis of a hematologic malignancy, including but not limited to Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma (HL), and Multiple Myeloma (MM).\n* Diagnosis of extramedullary disease\u002Flesions confirmed by one of the following: pathological biopsy, cytology, or at least one imaging modality (including PET-CT, contrast-enhanced CT, or contrast-enhanced MRI).\n* Presence of a suitable donor and scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n* Karnofsky Performance Status (KPS) score \\> 60% or Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2.\n* Has not participated in any other clinical trial involving cell-based or immunotherapies for the treatment of the primary disease.\n* The subject voluntarily agrees to participate in the study, demonstrates good compliance, and is willing to cooperate with follow-up procedures.\n* A signed informed consent form must be obtained prior to the initiation of any study-related procedures. For subjects aged 18 years or older, consent is to be provided by the subject or their immediate family member. If, in the physician's judgment, obtaining consent directly from the subject is not in the patient's best interest regarding their medical condition, the informed consent form may be signed by the legal guardian or an immediate family member of the patient\n\nExclusion Criteria:\n\n* Previous history of one or more autologous or allogeneic stem cell transplants prior to enrollment.\n* Uncontrolled infection at the time of enrollment, or requirement for mechanical ventilatory assistance, or hemodynamic instability.\n* Severe organ dysfunction, including but not limited to hepatic or renal impairment, and heart failure.\n* Evidence of active HIV replication; positive HCV antibody and detectable HCV-RNA within 90 days prior to enrollment; or positive HBsAg. Known seropositivity for HIV or active hepatitis C virus.\n* Presence of psychiatric disorders or any other condition that, in the investigator's opinion, would compromise the subject's ability to cooperate with study treatment and monitoring requirements.\n* Inability or unwillingness to provide written informed consent.\n* Any other condition or circumstance that, in the judgment of the investigator, may pose a risk to the subject or prevent the subject from meeting or fulfilling the study requirements.","60 Years",{"count":173,"type":21},20,[24],"Application of Stereotactic Body Radiotherapy (SBRT) Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Adult Hematological Malignance Patients with Extramedullary Lesions. This study aims to improve transplantation outcomes with extramedullary lesions. The investigators aim to study the Post-Transplantation Evaluation of Disease-Free Survival, Overall Survival, Treatment-Related Mortality, Cumulative Recurrence Rate, Post-Transplantation Complications, and Safety Data.",[177,29],"HSCT","2026-03-04",{"date":180,"type":34},"2026-03-06",{"date":182,"type":21},"2026-04-14",{"date":184,"type":21},"2028-03-01",{"name":186,"class":41},"Institute of Hematology & Blood Diseases Hospital, China",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":42},"100505851","discontinuation-study-100505851","NCT05866757","Discontinuation Study","Discontinuation of Maintenance Therapy for the Patients Diagnosed With Multiple Myeloma in Sustainable Minimal Residual Disease (MRD) Negative Remission Without High Risk Features","Inclusion Criteria:\n\n1. 18 years of age or over\n2. Patient with diagnosis of multiple myeloma as per IMWC in first line of treatment (induction, consolidation, ASCT, maintenance is considered single line therapy for the purpose of this study, also discontinuation of 1 maintenance regimen due to toxicity and start of another is considered single line therapy for the purpose of this study).\n3. Received at least 2 years of maintenance therapy, defined as any anti-myeloma therapy to prevent disease recurrence and prolong time in remission\n4. Patients who have discontinued maintenance therapy earlier than 2 years due to side effects but also achieved sustained MRD negative CR might be also included\n5. Patients must be able to understand and be willing to sign a voluntary informed consent form and agree to compliance with the protocol schedule, with the knowledge that they may withdraw consent at any time without impact on future medical care.\n\nExclusion Criteria:\n\n1. Patients who have received more than one line of therapy (induction, consolidation, ASCT, maintenance is considered single line therapy for the purpose of this study, also discontinuation of 1 maintenance regimen due to toxicity and start of another is considered single line therapy for the purpose of this study) or patients who have not completer two years of maintenance therapy, unless maintenance was discontinued voluntarily and the patient has achieved sustainable MRD negative remission..\n2. Patients with plasma cell disorders other than MM: lymphoplasmacytic lymphoma\u002FWaldenstrom macroglobulinemia, AL amyloidosis, POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes), etc…\n3. Prior organ transplant or condition requiring immunosuppressive therapy.\n4. Prior allogenic haematopoietic cell transplant\n5. Treatment with any investigational therapy that does not include maintenance as a part of the treatment strategy.\n6. Unable to sign an informed consent form.",{"count":195,"type":21},70,[24],"An interventional, non-randomised study to assess the risk of progression after discontinuation of maintenance therapy in sustained MRD negative complete remission by flow cytometry MM patients without high-risk features who have completed at least two years of maintenance therapy or who have discontinued maintenance due to side effects. The primary endpoint is to assess the rates of sustained MRD negativity by NGF in the bone marrow at 12 months after discontinuation of maintenance therapy.",[199,61,29],"Multiple Myeloma",[199,61],"2026-03-02",{"date":178,"type":34},{"date":204,"type":34},"2023-08-28",{"date":206,"type":21},"2028-07",{"name":208,"class":41},"University College Cork",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":230,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":42},"100596191","the-florida-ascent-study-100596191","NCT07042243","The Florida ASCENT Study","The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)","Patient Eligibility Inclusion Criteria:\n\n1. ≥18 years old.\n2. Pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months.\n3. Self-reported ability to read and speak English.\n4. Able to provide informed consent.\n5. Participant must not be considered a \"vulnerable population\" (pregnant women, neonates, children etc.)\n\nPatient Eligibility Exclusion Criteria:\n\n1. ≤18 years old.\n2. Participant do not have a pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months.\n3. Participant does not live within the state of Florida.\n\n3\\) Does not self-reported ability to read and speak English or Spanish. 4) Not able to provide informed consent. 5) Participant is considered a \"vulnerable population\" (pregnant women, neonates, children etc.)\n\nProvider Eligibility Inclusion Criteria\n\n1. ≥18 years old.\n2. Currently works as a physician, physician assistant, patient navigator and\u002For health system\u002Fadministrative leader in UF and UM affiliated clinics.\n3. Self-reported ability to read and speak English or Spanish.\n4. Able to provide informed consent.\n5. Participant must not be considered a \"vulnerable population\" (pregnant women, neonates, children etc.)\n\nProvider Eligibility Exclusion Criteria\n\n1. ≤ 18 years old.\n2. Does not currently works as a physician, physician assistant, patient navigator and\u002For health system\u002Fadministrative leader in UF and UM affiliated clinics.\n3. Does not self-report having the ability to read and speak English.\n4. Not able to provide informed consent.\n5. Participant is considered a \"vulnerable population\" (pregnant women, neonates, children etc.)","100 Years",{"count":85,"type":21},[24],"The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with cancer.\n\nThe main hypotheses it aims to test are:\n\n* At the patient level, the intervention will result in higher levels of food security, self- efficacy for dietary behaviors, and higher diet quality than standard care.\n* At the provider level, the intervention will be feasible, acceptable, appropriate, and able to enhance individualized care for patient wellness.\n\nResearchers will compare cancer patients receiving the MyCarePulse and ASCENT patient navigator intervention to those receiving standard care, to see if the intervention improves food security, self-efficacy, and diet quality.\n\nPhase 1\n\nPatient Participants will:\n\n* Complete the ASCENT Questionnaire, which is comprised of the following:\n\n  * U.S. Food Security Survey Module (U.S. FSSM)\n  * Patient-Reported Outcomes Measurement Information System (PROMIS-29)\n  * Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool\n* Be assessed using the Veggie Meter instrument\n* Participate in two semi-structured interviews\n\nProvider Participants will:\n\n•Participate in one semi-structured interview\n\nPhase 2\n\nPatient Participants will:\n\n* Participate in ASCENT patient navigator screenings and consultations\n* Complete the ASCENT Questionnaire, which comprises the U.S. FSSM, PROMIS-29, and ASA24®",[61,221,222,223,224,225,116,27,119,29,226,227,228,229],"Food Deprivation","Food Habits","Food Selection","Colorectal Cancer","Prostate Cancer","Skin Cancer","Melanoma","Nutrition Poor","Nutritional Deficiency",[231,61,232,233,234,235],"Food Insecurity","Food Access","Community-Informed Research","Nutritional Needs","Mixed-Methods","2026-02-19",{"date":238,"type":34},"2026-02-20",{"date":240,"type":34},"2025-12-05",{"date":242,"type":21},"2027-08",{"name":244,"class":41},"University of Florida",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":42},"100620482","early-phase-1-addition-of-venetoclax-to-combined-hematopoietic-stem-cell-and-kidney-transplantation-100620482","NCT07358195","Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation","Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy","Recipient Inclusion Criteria:\n\n* Patient ages 18-70\n* Underlying hematological malignancy which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT voting team.\n* Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS. Patient should be in a partial (PR) or complete remission (CR) at the time of the transplant.\n* Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation\n* LVEF \\> 40% as measured by echocardiography or MUGA\n* FEV1, FVC, and DLCO \\> 50% of predicted as measured by standard PFTs\n* Total bilirubin \\\u003C 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all \\\u003C 5x institutions upper limit of normal\n* ABO compatibility in the host vs. graft direction\n* Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.\n* Participants should be on dialysis or have a CrCl ≤ 35 ml\u002Fmin\n* Life expectancy greater than 6 months\n* Recipient ability to understand and provide informed consent\n\nDonor Inclusion Criteria:\n\n* HLA matched or haploidentical relative as defined by 3\u002F6, 4\u002F6, or 5\u002F6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age\n* ECOG performance status 0 or 1\n* Excellent health per conventional pre-donor history (medical and psychosocial evaluation)\n\n  • Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \\\u003C 3 times the upper limit of normal and normal creatinine)\n* Compatible ABO blood group\n* Negative donor lymphocyte cross match\n* No positive testing for active viral infection (Hepatitis B, Hepatitis C, HIV)\n* Donor ability to understand and provide informed consent\n* Meets standard institutional criteria for both bone marrow or peripheral blood stem cell (PBSC) and kidney donation\n\nExclusion Criteria:\n\n* Active serious infection\n* Participation in other investigational drug use at the time of enrollment\n* Positivity for active infection with HIV, HCV, or HBV\n* ABO blood group incompatibility in the host-vs-graft direction","70 Years",{"count":254,"type":21},3,[256],"EARLY_PHASE1","The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.",[259,260,261,262,29],"Kidney Failure Chronic","Stem Cell Transplant","Stem Cell Transplant Complications","Tolerance","2026-01-13",{"date":265,"type":34},"2026-01-22",{"date":267,"type":21},"2026-07",{"date":269,"type":21},"2029-12",{"name":271,"class":41},"Massachusetts General Hospital",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100614972","precision-physical-exercise-for-personalized-onco-hematology-100614972","NCT07286539","Precision Physical Exercise for Personalized Onco-Hematology.","PEPOH","Inclusión criteria:\n\n* Adult patients (≥18 years), capable of signing the informed consent and willing to participate in the study.\n* Performance status (ECOG) 0-2.\n* Specific inclusion criteria are defined for each cohort involved in the study as follows:\n\nLung cancer: Patients diagnosed with non-small cell lung carcinoma in metastatic stage, eligible for combined immunotherapy and chemotherapy, with active treatment.\n\nColorectal cancer: Patients with stage II, III, or IV resected colorectal cancer undergoing adjuvant chemotherapy.\n\nBreast cancer: Female patients with histologically confirmed hormone receptor-positive\u002FHER2-negative breast cancer, receiving active hormonal therapy (tamoxifen, aromatase inhibitor, or fulvestrant) in either adjuvant or stable metastatic phase.\n\nChronic lymphocytic leukemia (CLL): Patients diagnosed with CLL who have not received and are not in need of pharmacological treatment.\n\nMultiple myeloma (MM): Patients with a confirmed new diagnosis of MM under active first line treatment and non-candidates to autologous transplantation.\n\nExclusion criteria:\n\n* Presence of unstable bone metastases or extensive bone involvement associated with a high risk of fracture.\n* Uncontrolled cardiovascular, respiratory, musculoskeletal, or metabolic diseases that contraindicate physical exercise at the investigator's discretion.\n* Explicit medical contraindication to exercise training.\n* Documented poor adherence (\\\u003C80%).\n* Treatment discontinuation, disease progression, intolerance, or any other medical, personal, or logistical circumstance that, in the opinion of the investigators, may compromise participant safety or the integrity of the study.",{"count":280,"type":21},150,[24],"Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients. However, the biological mechanisms underlying these benefits remain poorly understood, especially during active treatment. The PEPOH project (Precision physical Exercise for Personalized Onco-Hematology) proposes a single-center clinical trial conducted at the Fundación del Instituto de Investigación Biomédica de Salamanca (FIBSAL) including five different patient cohorts: lung, colorectal (CRC), and breast cancer, chronic lymphocytic leukemia, and multiple myeloma. Participants will be randomly assigned to either an in-person intervention group, performing a supervised strength training program twice a week for 12 weeks combined with a home-based exercise program, or a control group performing only the home-based program. Biological samples will be collected before and after the intervention for multi-dimensional characterization (Genomics, Transcriptomics, Proteomics and Metabolomics) and systematic integration with parameters of functional capacity, quality of life, psychological well-being, frailty, and body composition. The main objective of the project is to determine biological parameters associated with strength exercise and their relationship with clinical parameters related to prognosis, therapy response and survival. This multi-dimensional approach will enable the detection of exercise adaptation biomarkers and generate knowledge about the mechanisms linking exercise with improved health outcomes in individuals with cancer. PEPOH will contribute to biomedical science and will enhance the comprehensive care of oncohematologic patients by integrating multi-omic and clinical data into a precision exercise model. This project will also contribute to society by offering a cost-effective, safe, and transferable intervention, which increases the overall quality of life.",[29,117,27,57,284,116],"Chronic Lymphocytic Leukemia (CLL)",[286,61,287],"Exercise","Well-being","2025-12-12",{"date":290,"type":34},"2025-12-16",{"date":292,"type":21},"2026-04-01",{"date":294,"type":21},"2030-12-31",{"name":296,"class":41},"University of Salamanca",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":254},"100468120","surge-supporting-underrepresented-minorities-in-genomics-based-cancer-trial-enrollment-intervention-100468120","NCT05375643","SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)","Inclusion Criteria:\n\n* Adult (age 18 years or older)\n* Black, Latinx, OR older adult (age 70 years or older)\n* Scheduled for a new patient consultation\n* Suspected or confirmed advanced malignancy (requiring active treatment)\n* Gastrointestinal, hematologic, or thoracic cancer\n* DFCI patient at Longwood\u002FChestnut Hill, DFCI satellite at St. Elizabeth's Medical Center, or DFCI satellite at Merrimack Valley\n\nExclusion Criteria:\n\n* Malignancy or former malignancy that requires only surveillance\n* Not continuing care at a participating DFCI site\n* Speaks a language other than English or Spanish\n* Unable to provide consent",{"count":304,"type":21},210,[24],"SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.",[28,29,308],"Thoracic Cancer",[28,29,308],"2025-11-04",{"date":312,"type":34},"2025-11-05",{"date":314,"type":34},"2023-04-03",{"date":316,"type":21},"2028-07-30",{"name":318,"class":41},"Nadine McCleary, MD, MPH",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":42},"100511703","hypnosis-a-path-to-appeasement-100511703","NCT05942885","Hypnosis: a Path to Appeasement","HYCVA","Inclusion Criteria:\n\n* Patients over 18 years old, fluent in French.\n* Patients starting hypnotherapy for anxiety disorders.\n* Anxiety score on the HADS scale (Hospital Anxiety and Depression Scale) greater than or equal to 8\u002F21\n* Patients with diffuse large cell B-cell lymphoma or follicular lymphoma, whatever the stage of the disease.\n* Diagnosis announcement less than 2 months old\n\nExclusion Criteria:\n\n* Persons deprived of their liberty by a judicial or administrative decision\n* Adults subject to a legal protection measure",{"count":327,"type":21},50,[24],"Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...).\n\nThe patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need.\n\nSeveral scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. On the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.",[29],[332,333,334,335],"hypnosis","Diffuse large cell B-cell lymphoma","follicular lymphoma","anxiety","2025-09-05",{"date":338,"type":34},"2025-09-11",{"date":340,"type":34},"2023-10-30",{"date":342,"type":21},"2026-07-30",{"name":344,"class":41},"Hospices Civils de Lyon",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":17,"minAge":353,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":42},"100476251","an-exploratory-study-to-evaluate-immune-determinants-of-the-response-to-adoptive-cell-therapy-act-in-solid-and-hematologic-tumors-100476251","NCT05481502","An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors","A Prospective Trial to Evaluate Immune Determinants of the Response and the Toxicity to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors","PIONEER","Inclusion Criteria:\n\n* Patient affiliated to a social security regimen\n* Tumor lesion accessible to core biopsies\n* Patient who is fully informed, able to comply with the protocol and who signed the informed consent\n* Pediatric patients \\> than 2 years old can be included\n* No restriction about the Eastern Cooperative Oncology Group (ECOG) status\n\nExclusion Criteria:\n\n* Coagulation abnormality prohibiting a biopsy (but patients can still give their consent for blood and bone marrow samples).\n* Tumor lesion not accessible to core biopsies.\n* Pregnant or nursing women cannot participate in this study.","2 Years",{"count":355,"type":21},160,[24],"This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.\n\nThe second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and\u002For toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and\u002For toxicity.",[359,360,29],"Solid Tumor, Adult","Solid Tumor, Childhood","2025-06-23",{"date":363,"type":34},"2025-06-24",{"date":365,"type":34},"2022-06-08",{"date":98,"type":21},{"name":368,"class":41},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":42},"100536075","photobiomodulation-for-oral-mucositis-and-functional-impairments-during-hematopoietic-stem-cell-transplantation-100536075","NCT06260111","Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell Transplantation","Laser Photobiomodulation to Prevent Oral Mucositis and Functional Impairment Among Adult Hematologic Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation","POMFITT","Inclusion Criteria:\n\n* Adults over 18 years of age with hematological neoplasms who require medical indication of an HSCT according to the Transplant Committee at Clinica Dávila\n* With sufficient understanding of Spanish.\n\nExclusion Criteria:\n\n* Observed cognitive deficit\n* Patients who do not meet the criteria of clinical stability, progression of the disease, and that do not fulfill requirement of the National Hematopoietic Stem Cell Transplantation Program.\n* Participants with an oral infection from any type of Candida prior to HSCT.","65 Years",{"count":52,"type":21},[24],"The goal of this clinical trial is to test the efficacy of laser photobiomodulation in adult hematologic cancer patients undergoing hematopoietic stem cell transplantation (HSCT). The main questions it aims to answer are: • Is photobiomodulation with laser in the oral cavity, compared to standard care, effective in preventing oral mucositis and functional impairments in adult patients receiving HSCT? • What is the level of patient´s acceptability of photobiomodulation with laser in the oral cavity during HSCT? Participants once a day will receive photobiomodulation (diode laser device) in their oral cavity from the first day of transplantation conditioning until third day post-transplant. Researchers will compare with usual care to see if photobiomodulation helps preventing oral mucositis and functional impairment.",[29],[383,384,385,386,387],"Low level laser therapy","Hematopoietic stem cell transplantation","Oral mucositis","Physical fitness","Physical therapy","2024-07-09",{"date":390,"type":34},"2024-07-11",{"date":392,"type":34},"2024-06-10",{"date":394,"type":21},"2025-10-30",{"name":396,"class":41},"Universidad del Desarrollo",{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":4},"100485522","collection-of-sequential-samples-from-patients-with-malignant-myeloid-hemopathy-for-the-study-of-treatment-resistance-100485522","NCT05602168","Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance","Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance: HEMATOBIO.02-IPC 2021-061","Inclusion Criteria:\n\n1. Diagnosis of acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) or myeloproliferative syndrome according to the WHO classification 2016,\n2. Patient for whom a new line of therapy is initiated.\n3. Patient older than 18 years of age.\n4. Patient affiliated to the social security system or benefiting from such a system.\n5. Signed consent to participate.\n\nExclusion Criteria:\n\n1. Weight at inclusion \\\u003C 50 kg\n2. Participating in another clinical study that would cause the total amount of blood collection to exceed the and endanger the patient\n3. Person in an emergency situation, adult under legal protection (guardianship, curatorship, etc.) protection (guardianship, curatorship or safeguard of justice), or unable to express his or her consent.\n4. Impossibility to submit to the medical follow-up of the trial for geographical social or psychological reasons,\n5. Pregnant or breastfeeding women",{"count":405,"type":21},400,[24],"The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection associating blood or marrow samples from patients with LA, MDS and MPS marrow samples from patients with LA, MDS and MPS at diagnosis, during treatment and at relapse and relapse and clinical annotations.",[29],"2022-10-26",{"date":411,"type":34},"2022-11-01",{"date":413,"type":21},"2023-01",{"date":415,"type":21},"2030-01",{"name":417,"class":41},"Institut Paoli-Calmettes"]